CAMBRIDGE, Mass., May 23 /PRNewswire/ — Quanterix
Corporation, the single molecule diagnostics company focused on
developing and commercializing high sensitivity tests, announced
the publication of a breakthrough study of the company’s
proprietary technology that demonstrates an unprecedented
sensitivity for measuring a biomarker for prostate cancer
recurrence. The research article, featured on the cover of the June
issue (Volume 28, No. 6) of Nature Biotechnology, describes
how researchers developed a simple blood test using Quanterix’s
Single Molecule Array (SiMoA™)
technology to selectively capture and measure individual Prostate
Specific Antigen (PSA) molecules in prostate cancer patients.
The study showed that SiMoA was 1,700 times more sensitive
than standard hospital tests, potentially allowing for detection of
prostate cancer recurrence years earlier than current tests.
To demonstrate the clinical potential of SiMoA, PSA was measured
in serum from men who had undergone radical prostatectomy for
prostate cancer. For the majority of these patients PSA is
initially reported as undetectable following surgery, but may be
present at very low levels that predict the likelihood of disease
recurrence. The Quanterix test was so sensitive that it was
able to measure residual PSA levels in all samples tested.
The PSA levels had been reported to be undetectable in these
samples by standard tests, highlighting the sensitivity and
precision of the SiMoA technology.
“This paper demonstrates the extraordinary sensitivity provided
by our SiMoA platform. Its single molecule resolution has
allowed us to measure PSA at extremely low levels, rather than
having to wait until the cancer is more advanced,” said Dr. David C. Duffy, Senior Directo